A detailed history of Avidity Partners Management LP transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Avidity Partners Management LP holds 749,000 shares of RCKT stock, worth $8.66 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
749,000
Previous 1,100,000 31.91%
Holding current value
$8.66 Million
Previous $23.7 Million 41.59%
% of portfolio
0.85%
Previous 1.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.6 - $25.88 $6.18 Million - $9.08 Million
-351,000 Reduced 31.91%
749,000 $13.8 Million
Q2 2024

Aug 14, 2024

BUY
$20.66 - $26.72 $1.55 Million - $2 Million
75,000 Added 7.32%
1,100,000 $23.7 Million
Q1 2024

May 15, 2024

SELL
$26.16 - $30.74 $18.2 Million - $21.3 Million
-694,103 Reduced 40.38%
1,025,000 $27.6 Million
Q4 2023

Feb 14, 2024

BUY
$16.78 - $31.94 $2.21 Million - $4.21 Million
131,674 Added 8.29%
1,719,103 $51.5 Million
Q3 2023

Nov 14, 2023

BUY
$15.07 - $24.05 $3.94 Million - $6.29 Million
261,429 Added 19.72%
1,587,429 $32.5 Million
Q2 2023

Aug 14, 2023

BUY
$16.59 - $23.6 $1.35 Million - $1.93 Million
81,600 Added 6.56%
1,326,000 $26.3 Million
Q1 2023

May 15, 2023

SELL
$15.79 - $22.6 $4.46 Million - $6.39 Million
-282,687 Reduced 18.51%
1,244,400 $21.3 Million
Q4 2022

Feb 14, 2023

BUY
$15.5 - $22.76 $23.7 Million - $34.8 Million
1,527,087 New
1,527,087 $29.9 Million
Q1 2021

May 17, 2021

SELL
$43.34 - $65.91 $2.17 Million - $3.3 Million
-50,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$23.3 - $59.57 $1.17 Million - $2.98 Million
50,000 New
50,000 $2.74 Million
Q1 2020

May 15, 2020

SELL
$9.71 - $25.11 $291,300 - $753,300
-30,000 Closed
0 $0
Q4 2019

Jun 17, 2020

BUY
$11.07 - $24.23 $332,100 - $726,900
30,000 New
30,000 $683,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $875M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.